NCT05556824

Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD

CompletedPHASE2INTERVENTIONAL

Trial Details

Start: 2023-03-03Est. Completion: 2026-05-27

Enrollment target: 255 participants

Locations

Elite Clinical Studies LLC, Phoenix, Arizona, United States
Angel City Research, Los Angeles, California, United States
Wr-Msra, Llc, Lake City, Florida, United States
A Positive Clinical Research, Miami, Florida, United States
Advanced Gastroenterology Associates LLC, Palm Harbor, Florida, United States
Health Synergy Clinical Research, West Palm Beach, Florida, United States
West Palm Quality Research (WPQR), West Palm Beach, Florida, United States
EmVenio-Georgia (EMGA), Atlanta, Georgia, United States
WR-Mount Vernon Clinical Research (MVCR), Sandy Springs, Georgia, United States
Gastroenterology Associates of Western Michigan PLC (WMCR), Wyoming, Michigan, United States
M3 Wake Research (CPOR), Raleigh, North Carolina, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
SMS Clinical Research (SMSR), Mesquite, Texas, United States
A and U Family Medicine (NCR), Sugar Land, Texas, United States
University of Virginia Health System, Charlottesville, Virginia, United States

Gastro Esophageal Reflux Disorder

A randomized, open-label, multiple-dose, crossover phase 1 clinical trial to compare and evaluate the safety, pharmacoki…

Cheongju-si, South KoreaEst. completion Aug 2026

GerdEosinophilic Esophagitis

Background \& Significance Chronic benign esophageal disorders such as Gastroesophageal reflux disease (GERD) and eosino…

Milwaukee, United StatesEst. completion Jul 1, 2028

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.